These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma. Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425 [TBL] [Abstract][Full Text] [Related]
6. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306 [TBL] [Abstract][Full Text] [Related]
7. Novel approaches in the treatment of multiple myeloma. Abedi M; Elfenbein GJ Med Health R I; 2003 Aug; 86(8):231-5. PubMed ID: 14582216 [TBL] [Abstract][Full Text] [Related]
8. An update: health economics of managing multiple myeloma. Moeremans K; Annemans L Eur J Cancer; 2006 Jul; 42(11):1684-91. PubMed ID: 16781867 [TBL] [Abstract][Full Text] [Related]
9. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204 [TBL] [Abstract][Full Text] [Related]
10. Early chemosensitivity to VAD regimen predicts a favorable outcome after autologous stem cell transplantation in multiple myeloma. Patriarca F; Sperotto A; Filì C; Zaja F; Prosdocimo S; Fanin R Haematologica; 2002 Jul; 87(7):779-81. PubMed ID: 12091134 [TBL] [Abstract][Full Text] [Related]
11. Pegfilgrastim effectively mobilizes PBSC in a poor mobilizer multiple myeloma patient. Malerba L; Mele A; Leopardi G; Stramigioli S; Politi P; Visani G Eur J Haematol; 2006 May; 76(5):436-9. PubMed ID: 16480428 [TBL] [Abstract][Full Text] [Related]
12. Treatment of multiple myeloma in the targeted therapy era. Saad AA; Sharma M; Higa GM Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585 [TBL] [Abstract][Full Text] [Related]
13. Advances in therapy of multiple myeloma. Bladé J; Rosiñol L Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053 [TBL] [Abstract][Full Text] [Related]